Treatment of Restless Legs Syndrome With the Hypocretin Antagonist Suvorexant
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Suvorexant improves sleep latency and wake after sleep onset in patients with primary
insomnia, and is FDA approved for this condition.
However, no data exist on its effects in RLS, so far. The investigators consider that
suvorexant might provide a stable therapeutic efficacy for the long treatment, avoiding the
risk of augmentation of symptoms commonly seen under dopamine agonists.
Phase:
Phase 2
Details
Lead Sponsor:
Diego García-Borreguero, MD, PhD Rocío Prieto Pérez
Collaborators:
Diego Garcia-Borreguero, Paseo de la Habana 151, Madrid 28036, SPAIN Sleep Research Institute (Paseo de la Habana 151, Madrid 28036, SPAIN)